We deploy AI agents for regulated manufacturers who can't afford to get compliance wrong.
Life sciences companies have been promised that AI will transform their operations. The promise is real. But somewhere between the demo and the deployment, most AI initiatives stall. In regulated environments — where 21 CFR, ISO 13485, and cGMP govern every process — the failure rate is 95%.
Generic AI tools don't survive contact with your quality system. They weren't designed with an audit trail in mind. They don't know the difference between a CAPA effectiveness check and a deviation investigation. They can't tell you whether their outputs are 21 CFR Part 11 compliant. And when something goes wrong, you bear the consequence — not the vendor.
The big AI companies are aware of this gap. In May 2026, Anthropic and Goldman Sachs committed $1.5 billion to a joint venture built on one premise: the bottleneck in AI adoption is not the technology — it's the scarcity of experts who can implement it inside real business operations. OpenAI announced a parallel $4 billion venture hours later.
Both ventures will eventually reach life sciences companies. When they do, their engineers will spend months learning what RxQMSR already knows: how to design an AI agent that strengthens a 21 CFR quality system instead of exposing it.
RxQMSR was built at that intersection. Not retrofitted to it.
Book a half-day lab session. Walk in with your current operations. Walk out with your AI agent roadmap.